drugset / Trial / NCT01093755
Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (PPI) drug dexlansoprazole will lead to a greater decrease in levels of inflammatory mediators (compared to conventional PPIs) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.
Timeline
- Start
- 2010-03
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexlansoprazole | Other / unclassified | 60 mg | — |
| Comparator | Dexlansoprazole | Other / unclassified | 90 mg | — |
| Comparator | Omeprazole | Other / unclassified | 20 mg | — |
| Comparator | Omeprazole | Other / unclassified | 40 mg | — |
| Comparator | Omeprazole | Other / unclassified | 60 mg | — |